Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Open access
Motzer, Robert J., Hutson, Thomas E., Olsen, Mark R., Hudes, Gary R., Burke, John M., Edenfield, William J., Wilding, George, Agarwal, Neeraj, Thompson, John A., Cella, David, Bello, Akintunde, Korytowsky, Beata, Yuan, Jinyu, Valota, Olga, Martell, Bridget, Hariharan, Subramanian, Figlin, Robert A. · 2012 · Journal of Clinical Oncology

Abstract

Purpose: Sunitinib has shown antitumor activity with a manageable safety profile as metastatic renal cell carcinoma (RCC) treatment, when given by the standard intermittent schedule as well as a continuous daily dosing (CDD) schedule. A trial was conducted to compare the schedules. Patients and Methods: Patients with treatment-naive, clear cell advanced RCC were randomly assigned 1:1 to receive sunitinib 50 mg/d for 4 weeks followed by 2 weeks off treatment (schedule 4/2; n = 146) or 37.5 mg/d on the CDD schedule (n = 146) for up to 2 years. The primary end point was time to tumor progression. Results: Median time to tumor progression was 9.9 months for schedule 4/2 and 7.1 months for the CDD schedule (hazard ratio, 0.77; 95% CI, 0.57 to 1.04; P = .090). No significant difference was observed in overall survival (23.1 v 23.5 months; P = .615), commonly reported adverse events, or patient-reported kidney cancer symptoms. Schedule 4/2 was statistically superior to CDD in time to deterioration, a composite end point of death, progression, and disease-related symptoms (P = .034). Conclusion: There was no benefit in efficacy or safety for continuous dosing of sunitinib compared with the approved 50 mg/d dose on schedule 4/2. Given the numerically longer time to tumor progression with the approved 50 mg/d dose on schedule 4/2, adherence to this dose and schedule remains the treatment goal for patients with advanced RCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.36.4133

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 275

Metadata

Authors
Motzer, R. J., Hutson, T. E., Olsen, M. R., Hudes, G. R., Burke, J. M., Edenfield, W. J., Wilding, G., Agarwal, N., Thompson, J. A., Cella, D., Bello, A., Korytowsky, B., Yuan, J., Valota, O., Martell, B., Hariharan, S., & Figlin, R. A.
Venue
Journal of Clinical Oncology
Published
2012-04-20
Volume
30
Issue
12
Pages
1371-1377
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2155319477
Cited by
275
References
14
FWCI
32.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1200/jco.2011.36.4133
The paper
Motzer, R. J., Hutson, T. E., Olsen, M. R., Hudes, G. R., Burke, J. M., Edenfield, W. J., Wilding, G., Agarwal, N., Thompson, J. A., Cella, D., Bello, A., Korytowsky, B., Yuan, J., Valota, O., Martell, B., Hariharan, S., & Figlin, R. A. (2012). Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.36.4133

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.